Matthew Hamilton Rosenberg’s Bio-Rad Laboratories Class A BIO Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30	Closed	-$10.2K	–	813
2024 Q1	$10.2K	Sell	30 -30	-50%	-$9.87K	﹤0.01%	604
2023 Q4	$19.4K	Hold	60	–	–	0.01%	541
2023 Q3	$21.5K	Hold	60	–	–	0.01%	525
2023 Q2	$22.7K	Sell	60 -39	-39%	-$15.9K	0.01%	527
2023 Q1	$47.4K	Hold	99	–	–	0.02%	474
2022 Q4	$41.6K	Hold	99	–	–	0.01%	507
2022 Q3	$41K	Hold	99	–	–	0.02%	485
2022 Q2	$50K	Buy	99 +39	+65%	+$20.3K	0.02%	455
2022 Q1	$34K	Hold	60	–	–	0.01%	503
2021 Q4	$45K	Hold	60	–	–	0.02%	429
2021 Q3	$45K	Hold	60	–	–	0.02%	410
2021 Q2	$39K	Hold	60	–	–	0.02%	395
2021 Q1	$34K	Hold	60	–	–	0.02%	380
2020 Q4	$35K	Hold	60	–	–	0.02%	365
2020 Q3	$31K	Hold	60	–	–	0.02%	348
2020 Q2	$27K	Buy	+60	New	+$26.5K	0.02%	376

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Matthew Hamilton Rosenberg's BIO Position: Q2 2024 in Review

Matthew Hamilton Rosenberg sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 30 shares — an estimated $10.2K sold.

Matthew Hamilton Rosenberg first reported a position in BIO in Q2 2020 and held it in 16 quarters. The position peaked at $50K in Q2 2022. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

Matthew Hamilton Rosenberg reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
Matthew Hamilton Rosenberg sold 30 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $10.2K.
Matthew Hamilton Rosenberg first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 16 quarters.
Matthew Hamilton Rosenberg's Bio-Rad Laboratories Class A position peaked at $50K in Q2 2022.
440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Matthew Hamilton Rosenberg's 13F filing for Q2 2024, filed 26 Jul 2024.